Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of BL-M07D1 in Subjects With HER2 Expressing Advanced Malignant Solid Tumors

NCT06293898 is registered in ClinicalTrials.gov with SystImmune Inc. as lead sponsor.

NCT NCT06293898
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06293898 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of BL-M07D1 in Subjects With HER2 Expressing Advanced Malignant Solid Tumors
Lead sponsor
SystImmune Inc.
Phase
Phase 1
Overall status
Recruiting
Start date
February 9, 2024
Completion date
April 15, 2029
Enrollment
280 (estimated)
Sites
26

Conditions

As the registry lists them; a condition with its own page is linked.

biliary tract cancer, breast cancer, cervical cancer, endometrial cancer, esophageal cancer, gastric cancer, gastroesophageal-junction cancer, lung cancer, ovarian cancer, urothelial carcinoma